Amgen CEO: "I felt real economic pain"

What do you do when your biggest therapeutic earners are swooning, your stock price is down and analysts have turned scornful? Look for that silver lining. That was Amgen CEO Kevin Sharer's approach yesterday when he was confronted by an angry horde of shareholders at the company's annual meeting. While conceding that last year was 'awful,' the chief executive of one of the biggest biotechs in the world said Amgen was off to a good start in '08. And those troubles the company is facing aren't really all that different from the woes faced by other big drug companies.

It was a tough sell. Even with his income down by 29 percent compared to 2006, steamed shareholders questioned Sharer's $13.2 million in compensation ($19 million according to SEC filings), his driver and car and use of the company plane.

Hey, responded Sharer, his shares are down too. "I felt real economic pain," he told the group. With Amgen shares down 30 percent from the 52-week high and Aranesp sales off by 20 percent, there was plenty of pain to go around the room.

- check out the article from the Los Angeles Times

Related Articles:
CEO pay: Who makes what in Big Biotech?
Amgen CEO touts blockbuster potential of D-mab
Amgen discusses the future with analysts
Amgen in crisis? Not us, says CEO Sharer

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.